2nd Department of Obstetrics and Gynecology, Athens University, Medical School, Aretaieion Hospital, Vasilissis Sofias Avenue, 76, 11528, Athens, PC, Greece.
Division of Endocrinology, Metabolism, and Diabetes, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, 11527, Athens, Greece.
Int Urogynecol J. 2024 Jun;35(6):1317-1322. doi: 10.1007/s00192-024-05809-0. Epub 2024 May 18.
Overactive Bladder Syndrome (OAB) significantly impacts quality of life, necessitating improved diagnostic tools and treatment monitoring. This study explores the potential of neurotrophins, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) as urinary biomarkers in patients with OAB undergoing mirabegron therapy, a β3-adrenergic agonist. This investigation is aimed at providing insights into the potential of neurotrophins to enhance OAB diagnosis and assess treatment efficacy.
Urinary NGF and BDNF levels were measured in 15 healthy controls and 30 patients with OAB. Patients were treated with mirabegron 50 mg once daily. Urinary NGF and BDNF levels were measured by enzyme-linked immunosorbent assay method and normalized by urinary creatinine levels (NGF/Cre and BDNF/Cre). The urinary NGF/Cre and BDNF/Cre levels were compared between controls and patients with OAB and subsequently at baseline and 3 months after mirabegron treatment. Treatment efficacy was assessed with the Indevus Urgency Severity Scale (IUSS) questionnaire.
Urinary NGF/Cre and BDNF/Cre levels were significantly higher in patients with OAB than in the controls (p < 0.001 and p = 0.03 respectively). Moreover, NGF/Cre and BDNF/Cre levels significantly decreased post-mirabegron treatment (p < 0.001 and p = 0.005 respectively). Patients with improvement of OAB symptoms after treatment showed lower levels of NGF/Cre at the 3-month evaluation than those with no improvement (p = 0.05).
Although both NGF/Cre and BDNF/Cre levels were significantly decreased after mirabegron treatment, only NGF/Cre levels were associated with treatment response.
膀胱过度活动症（OAB）显著影响生活质量，因此需要改进诊断工具和治疗监测。本研究探讨了神经生长因子（NGF）和脑源性神经营养因子（BDNF）作为接受米拉贝隆治疗的 OAB 患者的尿生物标志物的潜力，米拉贝隆是一种β3-肾上腺素能激动剂。本研究旨在探讨神经生长因子在增强 OAB 诊断和评估治疗效果方面的潜力。
测量了 15 名健康对照者和 30 名 OAB 患者的尿 NGF 和 BDNF 水平。患者接受米拉贝隆 50mg 每日一次治疗。通过酶联免疫吸附测定法测量尿 NGF 和 BDNF 水平，并通过尿肌酐水平（NGF/Cre 和 BDNF/Cre）进行标准化。比较了对照组和 OAB 患者之间的尿 NGF/Cre 和 BDNF/Cre 水平，然后在基线和米拉贝隆治疗 3 个月后进行比较。使用 Indevus 急迫严重程度量表（IUSS）问卷评估治疗效果。
OAB 患者的尿 NGF/Cre 和 BDNF/Cre 水平明显高于对照组（p<0.001 和 p=0.03）。此外，米拉贝隆治疗后 NGF/Cre 和 BDNF/Cre 水平明显降低（p<0.001 和 p=0.005）。治疗后 OAB 症状改善的患者在 3 个月评估时的 NGF/Cre 水平低于无改善的患者（p=0.05）。
尽管米拉贝隆治疗后 NGF/Cre 和 BDNF/Cre 水平均明显降低，但只有 NGF/Cre 水平与治疗反应相关。
